Substituted cinnamic acid derivatives as UV absorbers and uses thereof

Abstract

The present relates to compounds of formula (I) as defined herein. The compounds are suitable for protection against ultraviolet (UV) radiation. Further, the present invention is concerned with compositions comprising at least one compound of formula (I) and uses of said compounds as UV filters and light stabilizing agents.

Description

[0001] SUBSTITUTED CINNAMIC ACID DERIVATIVES AS UV ABSORBERS AND USES THEREOF

[0002] Field of the invention

[0003] The present invention relates to compounds according to formula (I), as defined herein below, that are useful as organic biodegradable UV absorbers, in particular in personal care and pharmaceutical compositions, such as sunscreen and daily care compositions with photoprotection. The present invention furthermore relates to such compositions containing the UV absorbers as well as their corresponding use.

[0004] Background of the invention

[0005] UV radiation causes harmful effects on the human skin. Beside the acute effect of sunburn of the skin, UV radiation is also known to increase the risk of skin cancer. Furthermore, long time exposure to UV-A and UV-B light can cause phototoxic and photo allergenic reactions on the skin and can accelerate skin aging.

[0006] To protect the human skin from UV radiation, various sun protecting UV filters (also referred to as UV absorbers) exist including UV-A filter, UV-B filter, and broadband filters. These filters are added to e.g. sunscreen or cosmetic compositions. The UV filters are either organic or inorganic, particulate or non- particulate compounds, of which all have a high absorption efficacy in the UV-light range. In general, UV light can be divided into UV-A radiation and UV-B radiation. Depending on the position of the absorption maxima, UV filters are divided into UV-A and UV-B filters. In case an UV filter absorbs both, UV-A and UV- B light, it is referred to as a broadband absorber.

[0007] Achieving a more sustainable chemical industry is one the clear objectives pursued by EU legislation, incorporating the replacement of ingredients having a negative environmental impact such as a negative effect on the endocrine system, persistence, bioaccumulation and or toxicity. In line with these objectives, EU regulations on the use of certain chemicals for some applications become increasingly strict. This is for instance the case for UV filters used in sunscreen applications and UV stabilizers for several other applications.

[0008] Current solutions on the market on the one hand are not fully biodegradable, and on the other hand present toxicity concerns. In fact, the vast majority of cosmetic registered organic UV filters are resistant to environmental degradation through chemical, biological, and photolytic processes. Because of their persistence, they bioaccumulate with potential adverse impact on human health and the environment. Due to their wide release into the environment, and especially in the oceans, the demand for biodegradable UV filters is growing.

[0009] In this context, cosmetics product regulations (CPR) will on a noticeably short timescale certainly ban many of the current solutions. In this context, innovative and more sustainable (biodegradable) UV filters and UV stabilizer solutions urgently need to be developed and brought to the market to replace current solutions

[0010] The present invention meets this demand by providing novel types of organic UV filters that are more biodegradable than currently used compounds. Summary of the invention

[0011] The present invention is based on the finding that specific compounds of formula (I) (2-cyano acrylic acid derivatives) as well as the salts, hydrates, tautomers, and stereoisomers thereof are suitable as UV absorbers while also being biodegradable.

[0012] In a first aspect, the present invention is thus directed to a compound of formula (I) or the salt, hydrate, tautomer or stereoisomer thereof; wherein

[0013] R1is -Phenyl-(OR4)

[0014] R2is H;

[0015] R3is selected from C2-C12 alkyl;

[0016] R4is -C(=O)R6;

[0017] R6is C1-C4 alkyl.

[0018] The salts are preferably pharmaceutically or cosmetically acceptable salts. The stereoisomers are preferably E / Z isomers. In various embodiments, the E conformation shown in formula (I) is the preferred conformation.

[0019] In various embodiments,

[0020] (1) R3is linear or branched C3-C12 alkyl, preferably C3-, C4-, C5-, Ce-, C7-, Cs-, C9-, or Cio-alkyl, for example C4-Cio-alkyl, such as Cs-Cg-alkyl, in particular Ce-Cs-alkyl, preferably Cs-alkyl, more preferably branched Cs-alkyl, most preferably 2-ethylhexyl; and / or

[0021] (2) R6is C1-C3 alkyl, preferably methyl or ethyl, more preferably methyl

[0022] In one embodiment, the compound is a compound according to formula (I); wherein the compound is a compound of formula (la) or a salt, hydrate, tautomer or stereoisomer thereof:

[0023] The compounds disclosed herein preferably have a biodegradability of at least 20% degradation, preferably at least 40% degradation, more preferably at least 60%, as determined over 28 days at 22°C according to OECD 301 F. Said biodegradability according to OECD 301 F may be determined as described herein below.

[0024] In another aspect, the present invention is directed to a composition, for example a pharmaceutical or personal care composition, comprising the organic biodegradable UV filters disclosed herein, either individually or in combination. Optionally, such a composition may also comprise a dermatologically acceptable emulsifier, thickener, or emollient.

[0025] In various embodiments, the compositions further comprise at least one further UV filter different to the compounds of formula (I).

[0026] This additional UV filter may be selected from organic and inorganic UV filters and may optionally be biodegradable. In various embodiments, such additional UV filter is selected from inorganic UV filters. In various embodiments, it may be selected from organic UV filters.

[0027] In various embodiments, the additional UV filter or combination thereof is selected from at least one UVA filter, preferably selected from the group consisting of disodium phenyl dibenzimidazole tetrasulfonate, hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate), methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate (MCE), 1-(4-(1 ,1-dimethylethyl)phenyl)-3-(4-methoxyphenyl)propane-1 ,3-dione (INCI butyl methoxydibenzoylmethane), terephthalylidene dicamphor sulfonic acid, and combinations thereof; and / or at least one UVB filter, preferably selected from the group consisting of 4,4’,4”-(1 ,3,5-triazine-2,4,6- triyltriimino)tris-benzoic acid-tris(2-ethylhexyl)ester (INCI ethylhexyl triazone), 4,4’-[[6-[[4-[[(1 ,1- dimethylethyl)amino]carbonyl]phenyl]amino]-1 ,3,5-triazin-2,4-diyl]3iamino]bis-benzoic acid-bis(2- ethylhexyl)ester (INCI diethylhexyl butamido triazone), phenylbenzimidazole sulfonic acid, , and combinations thereof; and / or at least one broadband UV filter, preferably selected from the group consisting of bis- ethylhexyloxyphenol methoxyphenyl triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine), 2-(2H- benzotriazol-2-yl)-6-[(2-ethylhexyloxy)methyl]-4-methylphenol, 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2- methyl-3-[1 ,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]-1-disiloxanyl]propyl]phenol (INCI drometrizole trisiloxane), 2,2'-methylenbis[6-(2H-benzotriazol-2-yl)-4-(1 ,1 ,3,3-tetramethylbutyl)phenol] (INCI methylene Bis-benzotriazolyl tetramethylbutylphenol), phenylene bis-diphenyltriazine (PBDT), and combinations thereof; and / or at least one organic particulate UV filter is selected from the group consisting of 2,2'-methylene bis[6- (2H-benzotriazol-2-yl)-4-(1 ,1 ,3,3-tetramethylbutyl)phenol] (INCI methylene bis-benzotriazolyl tetramethylbutylphenol), 2,4,6-tris(biphenyl-4-yl)-1 ,3,5-triazine (INCI tris-biphenyl triazine), 1 ,1 ’-(1 ,4- piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone (INCI bis- (diethylaminohydroxybenzoyl benzoyl) piperazine), 5,6,5’,6’-tetraphenyl-3-3’-(1 ,4-phenylene)bis(1 ,2,4- triazine) (INCI phenylene bis-diphenyltriazine, PBDT), micronized 1 ,4-di(benzoxazole-2'-yl)benzene and combinations thereof; and / or at least one inorganic UV filter, preferably selected from the group consisting of titanium dioxide, zinc oxide, iron oxide, cerium oxide and mixtures thereof. In various embodiments, the additional UV filter may be selected from the group consisting of ethylhexyl methoxycinnamate, ethylhexyl salicylate, homosalate, amiloxate, padimate O, shinorine, gadusol, mycosporine-2 glycine, porphyra-334, or cyanoacrylates other than those of formula (I), the cyanoacrylates optionally being selected from

[0028] In various embodiments, the composition further comprises at least one UV filter selected from the group consisting of croconic acid derivatives, N-[(3E)-3-[(4-Methoxyphenyl)imino]-5,5-dimethyl-1-cyclohexen-1- yl]glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, Ethyl (3R)-3,4,5,6,7,8-hexahydro-8-[(4- methoxyphenyl)imino]-6,6-dimethyl-2H-1 ,4-benzothiazine-3-carboxylate, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, feruloyl hemp glycerides, feruloyl glycerides, feruloyl soybean glyceride FSG-33, feruloyl coconut glyceride FCG-33, feruloyl hemp glyceride FHG-33, ferulic acid, caffeic acid phenethyl ester, quercetin, methylsalicylate, vanillic acid, menthyl anthranilate, rutin, hispolon, Bis(cyano butylacetate) anthracenediylidene, trolamine salicylate, resveratrol trimethyl ether, ethyl ferulate, chlorogenic acid, methyl vanillate, ethyl protocatechuate, genistein, ellagic acid, pongamol, daidzein, luteolin, acetovanillone, caffeic acid, kaempferol, apigenin, sinapic acid, folic acid, troxerutin, p-coumaric acid, melanin, 3,4,5-trimethoxycinnamic acid, Kaempferia galanga root extract, ethylhexyl methoxycrylene, protocatechu ic acid, lignin, lignosulfonate, coffee bean extract, mycosporine-like amino acids, gadusosporines, hipposudoric acid, norhipposudoric acid, 2-Methylphenyl (2E)-3-(4-methoxyphenyl)-2- propenoate, 2-Propenoic acid, 3-(4-methoxyphenyl)-, 2-methylphenyl ester. All the afore-mentioned compounds that are in acid form may be similarly used in form of a salt thereof and vice versa.

[0029] In various embodiments, the compositions, such as pharmaceutical or personal care composition, can additionally comprise one or more further biodegradable compounds, including those selected from the group consisting of C12-C15 alkyl benzoates, coco glycerides, coconut oil, dibutyl adipate, dodecyl lactate, ethylhexyl benzoate, glycerol, glyceryl stearate, lauryl glycoside, lauryl lactate, triglycerides, phenoxyethanol, phenoxy ethyl caprylate, polyglyceryl-2-dipolyhydroxy-stearate, stearoyl glutamate and the sodium salt thereof, stearyl alcohol, dicarboxymethyl alaninate and the sodium salt thereof, and xanthan gum as well as combinations thereof.

[0030] In a still further aspect, the present invention is directed to the compounds or compositions described herein for use to protect skin against UV radiation.

[0031] In still another aspect, the present invention relates to the use of a compound of formula (I) or the salt, hydrate, tautomer or stereoisomer thereof; wherein

[0032] R1is -Phenyl-(OR4)

[0033] R2is H;

[0034] R3is selected from C2-C12 alkyl;

[0035] R4is -C(=O)R6;

[0036] R6is C1-C4 alkyl, as an organic UV filter or as a light stabilizer to protect ingredients against photolytic degradation in a pharmaceutical, personal care or home care composition, wherein the compound preferably has a biodegradability of at least 20% degradation as determined over 28 days at 22°C according to OECD 301 F.

[0037] In various embodiments, said use as an organic UV filter or as a light stabilizer to protect ingredients against photolytic degradation in a pharmaceutical, personal care or home care composition includes the compounds defined above in the former aspects of the invention, i.e. the compounds disclosed herein are used accordingly.

[0038] In various embodiments of the composition or the use, the compound of formula (I) as described herein above is comprised in said composition in an amount relative to the total weight of the composition of 0.5 to 50 wt.-%, preferably from 1 to 45 wt.-%, more preferably from 2 to 40 wt.-%, and in particular from 2.5 to 35 wt.-%.

[0039] Detailed description

[0040] Before describing embodiments of the present invention in detail, definitions important for understanding the present invention are given.

[0041] As used in this specification and in the appended claims, the singular forms of "a" and "an" also include the respective plurals unless the context clearly dictates otherwise.

[0042] In the context of the present invention, the terms "about" and "approximately" denote an interval of accuracy that a person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates a deviation from the indicated numerical value of ±20%, preferably ±15%, more preferably ±10%, and even more preferably ±5%. It is to be understood that the term "comprising" is not limiting. For the purposes of the present invention, the term "consisting of is considered to be a preferred embodiment of the term "comprising of. If hereinafter a group is defined to comprise at least a certain number of embodiments, this is meant to also encompass a group, which preferably consists of these embodiments only.

[0043] Furthermore, the terms "first", "second", "third" or "(i)", "(ii)", "(iii)", "(iv)" etc. and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.

[0044] As used herein the term “free of in the context that the composition of the present invention is free of a specific compound or group of compounds, which may be combined under a collective term, means that the composition does not comprise said compound or group of compounds in an amount of more than 0.8% by weight, based on the total weight of the composition. Furthermore, it is preferred that the composition according to the present invention does not comprise said compounds or group of compounds in an amount of more than 0.5% by weight, preferably the composition does not comprise said compounds or group of compounds at all. The same definition is applied for the term “does not comprise”. Furthermore, it is to be understood that the term “free of’ or “does not comprise”, in case the composition does not comprise a compound X and a compound Y means that the compositions must be free of both compounds X and Y. In other words, the composition may not contain any compound selected from X and Y.

[0045] When referring to compositions and the weight percent of the therein comprised ingredients it is to be understood that according to the present invention the overall amount of ingredients does not exceed 100% (± 1 % due to rounding).

[0046] It is to be understood that this invention is not limited to the particular methodology, protocols, reagents etc. described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention that will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0047] The term "compound(s) according to the invention", or "compounds of formula (I)" comprises the compound(s) as defined herein as well as a stereoisomer or tautomer thereof.

[0048] Depending on the substitution pattern, the compounds according to the invention may have one or more centers of chirality. The invention provides both the single pure enantiomers or pure diastereomers of the compounds according to the invention, and their mixtures and the use according to the invention of the pure enantiomers or pure diastereomers of the compounds according to the invention or their mixtures. Suitable compounds according to the invention also include all possible geometrical stereoisomers (cis / trans isomers or E / Z isomers) and mixtures thereof. The term "stereoisomer(s)" encompasses both optical isomers, such as enantiomers or diastereomers, the latter existing due to more than one center of chirality in the molecule, as well as geometrical isomers (cis / trans isomers). The present invention relates to every possible stereoisomer of the compounds of formula (I), i.e. to single enantiomers or diastereomers, as well as to mixtures thereof.

[0049] The compounds of formula (I) may be amorphous or may exist in one or more different crystalline states (polymorphs) which may have different macroscopic properties such as stability or show different biological properties such as activities. The present invention relates to amorphous and crystalline compounds of formula (I), mixtures of different crystalline states of the respective compound of formula (I).

[0050] Tautomers may be formed, if a substituent is present at the compound of formula (I), which allows for the formation of tautomers such as keto-enol tautomers or the like.

[0051] The organic moieties mentioned in the above definitions of the variables are collective terms for individual listings of the individual group members. The prefix Cn-Cmindicates in each case the possible number of carbon atoms in the group.

[0052] The term "alkyl" as used herein denotes in each case a straight-chain or branched alkyl group having usually from 1 to 8 carbon atoms, preferably from 1 to 4 carbon atoms. Examples of an alkyl group are methyl, ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl, n-pentyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1 -ethyl propyl, 1 ,1 -dimethylpropyl, 1 ,2-dimethylpropyl, n- hexyl, 2-ethylhexyl and the like.

[0053] The term “C(=O)” as used therein denotes in each case a carbonyl moiety.

[0054] The term “C(=O)-(Cn-Cm-alkyl)” as used herein denotes in each case an alkylcarbonyl, referring to a straight-chain or branched alkyl group as defined above, which is bonded via the carbon atom of a carbonyl group C(=O) to the remainder of the molecule.

[0055] The term “aryl” or “aromatic carbocycle” preferably includes 6-membered aromatic carbocyclic rings based on carbon atoms as ring members. A preferred example is phenyl. The term also includes compounds which comprise fused aromatic or fused aromatic and non-aromatic rings, such as indane or tetrahydronaphthalene. “Carbocyclic”, as used herein, additionally includes non-aromatic cyclic compounds having only carbon ring atoms, such as cyclopentane or cyclohexane.

[0056] The term “heterocyclic” or “heterocyclyl” includes, unless otherwise indicated, in general a 3- to 9- membered, preferably a 4- to 8-membered or 5- to 7-membered, more preferably 5- or 6-membered, in particular 6-membered monocyclic ring. The heterocycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Hiickel rule for aromaticity is not fulfilled, whereas aromatic means that the Hiickel (4n + 2) rule is fulfilled. The heterocycle typically comprises one or more, e.g. 1 , 2, 3, or 4, preferably 1 , 2, or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. The remaining ring members are carbon atoms. In one embodiment, the heterocycle is an aromatic heterocycle, preferably a 5- or 6-membered aromatic heterocycle comprising one or more, e.g. 1 , 2, 3, or 4, preferably 1 , 2, or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. Examples of aromatic heterocycles are provided below in connection with the definition of “hetaryl”. “Hetaryls” or “heteroaryls” are covered by the term “heterocycles”. The saturated or partially or fully unsaturated heterocycles usually comprise 1 , 2, 3, 4 or 5, preferably 1 , 2 or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. The skilled person is aware that S, SO or SO2 is to be understood as follows:

[0057] Further, a skilled person is aware that resonance structures of the oxidized forms may be possible. Saturated heterocycles include, unless otherwise indicated, in general 3- to 9-membered, preferably 4- to 8-membered or 5- to 7-membered, more preferably 5- or 6-membered monocyclic rings comprising 3 to 9, preferably 4 to 8 or 5 to 7, more preferably 5 or 6 atoms comprising at least one heteroatom, such as pyrrolidine, tetrahydrothiophene, tetrahydrofuran, piperidine, tetrahydropyran, dioxane, morpholine or piperazine.

[0058] The term "hetaryl" or “heteroaryl” or “aromatic heterocycle” or “aromatic heterocyclic ring” includes monocyclic 5- or 6-membered aromatic heterocycles comprising as ring members 1 , 2, 3 or 4 heteroatoms selected from N, O and S, where S-atoms as ring members may be present as S, SO or SO2. Examples of 5- or 6-membered aromatic heterocycles include pyridyl (also referred to as pyridinyl), i.e. 2-, 3-, or 4-pyridyl , pyrimidinyl, i.e. 2-, 4- or 5-pyrimidinyl, pyrazinyl, pyridazinyl, i.e. 3- or 4-pyridazinyl, thienyl, i.e. 2- or 3- thienyl, furyl, i.e. 2-or 3-furyl, pyrrolyl, i.e. 2- or 3-pyrrolyl, oxazolyl, i.e. 2-, 3- or 5-oxazolyl, isoxazolyl, i.e. 3-, 4- or 5-isoxazolyl, thiazolyl, i.e. 2-, 3- or 5-thiazolyl, isothiazolyl, i.e. 3-, 4- or 5-isothiazolyl, pyrazolyl, i.e. 1-, 3-, 4- or 5-pyrazolyl, i.e. 1-, 2-, 4- or 5-imidazolyl, oxadiazolyl, e.g. 2- or 5-[1 ,3,4]oxadiazolyl, 4- or 5- (1 ,2,3-oxadiazol)yl, 3- or 5-(1 ,2,4-oxadiazol)yl, 2- or 5-(1 ,3,4-thiadiazol)yl, thiadiazolyl, e.g. 2- or 5-(1 ,3,4- thiadiazol)yl, 4- or 5-(1 ,2,3-thiadiazol)yl, 3- or 5-(1 ,2,4-thiadiazol)yl, triazolyl, e.g. 1 H-, 2H- or 3H-1 ,2,3-triazol-4-yl, 2H-triazol-3-yl, 1 H-, 2H-, or 4H-1 ,2,4-triazolyl and tetrazolyl, i.e. 1 H- or 2H-tetrazolyl.

[0059] When referring to compositions and the weight percent of the therein comprised ingredients it is to be understood that according to the present invention the overall amount of ingredients does not exceed 100% (± 1 % due to rounding).

[0060] The term “personal care composition”, as used herein, refers to any product suitable to apply to the human body, e.g. sunscreen compositions, bath and shower products, preparations containing fragrances and odoriferous substances, hair-care products, dentifrices, decorative preparations, and cosmetic formulations containing active ingredients. Specific examples of personal care compositions are, without limitation, sunscreen compositions and daily care compositions. The term “sunscreen composition” refers to any topical product, which absorbs and may further reflect certain parts of UV radiation. Thus, the term “sunscreen composition” is to be understood as not only including sunscreen compositions, but also any cosmetic compositions that provide UV protection. The term “topical product” refers to a product that is applied to the skin and can refer, e.g., to sprays, lotions, creams, oils, or gels. The sunscreen composition comprises one or more active UV filtering agents, e.g., organic or inorganic UV filters, including those described herein, as well as other ingredients or additives, e.g., emulsifiers, emollients, viscosity regulators, sensory enhancer, stabilizers, film formers, UV boosters, UV scattering compounds, pH adjusters, preservatives, or perfumes. According to the present invention the sunscreen composition may comprise one or more active agents, e.g., organic UV filters, as well as other ingredients or additives, e.g., emulsifiers, emollients, viscosity regulators, stabilizers, preservatives, or fragrances.

[0061] A sunscreen composition of the present invention may inter alia be formulated as a water-in-oil (W / O) or an oil-in-water (O / W) dispersion, bi-phasic formulation, lipophilic gel, hydrophilic gel, a vesicular dispersion of an ionic or nonionic amphiphilic lipid, a gel, a solid stick or an aerosol formulation.

[0062] The term “daily care composition” refers to any topical product which is intended to be used daily without or with a UV protection. In case UV protection is included, it absorbs and may further reflect and scatter certain parts of UV radiation and is used as an everyday care product for the human body, e.g., for face or body, and is, in the context of the present invention, referred to as a “daily care composition with photoprotection”. The daily care composition with photoprotection of the present invention typically comprises one or more active agents, e.g., organic and / or inorganic UV filters, including those described herein, as well as other ingredients or additives, e.g., emulsifiers, emollients, viscosity regulators, stabilizers, sensory enhancers, humectants, film formers, UV scattering compounds, UV boosters, pH adjusters, adjuvants, preservatives, or fragrances. Suitable daily care composition with photoprotection according to the present invention are, e.g., leave-on face and body care products. Suitable leave-on products for face and body are, e.g., decorative preparations (or make-up) and skin care preparations.

[0063] Suitable decorative preparations are, e.g., facial make-up in the form of day creams or powder creams, face powder (loose or pressed), foundations, dry and moist make-up rouge or cream make-up, eye-care preparations, e.g. eyeshadow preparations, mascara, eyeliner, eye creams or eye-fix creams; lip-care preparations, e.g. lipsticks, rouge lip gloss, lip contour pencils, nail varnishes, and suntan lotions.

[0064] Suitable skin care preparations are, e.g., moisturizing, refining, and lifting preparations. The cited daily care compositions can be in the form of creams, ointments, pastes, foams, gels, lotions, powders, make-ups, sprays, sticks or aerosols.

[0065] Suitable bath and shower additives are, e.g., shower gels, bath-salts, bubble baths and soaps.

[0066] Suitable preparations containing fragrances and odoriferous substances are in particular scents, perfumes, toilet waters and shaving lotions (aftershave preparations). Suitable hair-care products are, e.g., shampoos for humans and animals, in particular dogs, hair conditioners, products for styling and treating hair, perming agents, hair sprays and lacquers, hair gels, hair fixatives and hair dyeing or bleaching agents.

[0067] Suitable dentifrices are, e.g., tooth creams, toothpastes, mouth-washes, mouth rinses, anti-plaque preparations and cleaning agents for dentures.

[0068] Suitable cosmetic formulations containing active ingredients are, e.g., hormone preparations, vitamin preparations, vegetable extract preparations and antibacterial preparations.

[0069] The cited body-care products can be in the form of creams, ointments, pastes, foams, gels, lotions, powders, make-ups, sprays, sticks or aerosols. They preferably contain the compound of formula (I) in the aqueous phase.

[0070] The term “pharmaceutical composition” refers to a composition containing at least one active ingredient that is used to treat (and thus alleviate) a disease, disorder or the symptoms of a disease or disorder. Also included are compositions that prevent a disease or disorder and thus act prophylactically.

[0071] “Home care composition”, as used herein, relates to cleaning compositions used for objections, such as general cleaning compositions, laundry and dishwashing detergents and the like. More specific example include, without limitation, liquid scouring agents, glass detergents, neutral cleaners (all-purpose cleaners), acid household cleaners (bath), WC cleaners, preferably in washing, rinsing and dishwashing agents, clear rinsing agents, dishwasher detergents, shoe polishes, polishing waxes, floor detergents and polishes, metal, glass and ceramic cleaners, textile-care products, agents for removing rust, color and stains (stain remover salt), furniture and multipurpose polishes and leather dressing agents (leather sprays). Typically, household cleaning agents are aqueous or alcoholic (e.g. ethanol or isopropyl alcohol) solutions of one or more of the following components: -anionic, nonionic, amphoteric and / or cationic surfactants -soaps, prepared by saponification of animal and vegetable greases -organic acids, like hydrochloric acid, phosphoric acid, or sulfuric acid, -for basic products inorganic (NaOH or KOH) or organic bases; -abrasives for improved cleaning of surfaces, -waxes and / or silicones for maintenance and protection of surfaces, - polyphosphates, -substances which eliminate hypochlorite or halogens; -peroxides comprising bleaching activators like TAED, for example sodium perborate or H2O2; -enzymes; -in washing detergents discoloration inhibitors, soil-release compounds, grey scale inhibitors, foam inhibitors, fluorescent whitening agents; -cleaning agents based on wax may comprise solvents selected from benzine, turpentine and / or paraffines and emulsifiers based on wax; -filling agents like silicates, polyphosphates, Zeolithes for powdery cleaning agents; -pigments, lakes or soluble dyes; -perfumes; and -light stabilizers, antioxidants and chelating agents.

[0072] The term “light stabilizers” as used herein are compounds suitable for protecting other compounds or compositions against photolytic degradation. The light stabilizer is usually present in such products in a concentration of 50 to 1000 ppm. The term “UV-filter” as used herein refers to organic or inorganic compounds, which can absorb may further reflect and scatter UV radiation caused by sunlight. UV-filter can be classified based on their UV protection curve as UV-A, UV-B or broadband filters. Preferably, the term “UV filter” comprises or consists of any UV filter as defined in the Annex VI (version of 11.11.2022) of the Regulation (EC) No 1223 / 2009 of the European Parliament and of the Council.

[0073] The definition of “broadband” protection (also referred to as broad-spectrum or broad protection) may be based for example on the “critical wavelength” or the UVA-PF (UVA protection factor). For broadband coverage, UV-B and UV-A protection must be provided. According to the US requirements, a critical wavelength of at least 370 nm is required for achieving broad spectrum protection. Furthermore, it is recommended by the European Commission that all sunscreens should have an UVA protection factor, which is at least one third of the labelled sun protection factor (SPF), e.g., if the sunscreen composition has an SPF of 30 the UVA protection factor has to be at least 10.

[0074] The term “critical wavelength” is defined as the wavelength at which the area under the UV protection curve (% protection versus wavelength) represents 90 % of the total area under the curve in the UV region (290- 400 nm). For example, a critical wavelength of 370 nm indicates that the protection of the sunscreen composition is not limited to the wavelengths of UV-B, i.e., wavelengths from 290-320 nm, but extends to 370 nm in such a way that 90 % of the total area under the protective curve in the UV region are reached at 370 nm.

[0075] The term “photostability” refers to the ability of a UV filter or any other molecule, which is exposed to sunlight, to stay stable upon irradiation. In particular, this means that the compound does not undergo a degradation process upon UV radiation.

[0076] The term “sun protection factor (SPF)” as used herein indicates how well the skin is protected by a sunscreen composition from an erythema (sunburn) induced mainly from UV-B radiation. In particular, the factor indicates how much longer the protected skin may be exposed to the sun without getting a sunburn in comparison to untreated skin. For example, if a sunscreen composition with an SPF of 15 is evenly applied to the skin of a person usually getting a sunburn after 10 minutes in the sun, the sunscreen allows the skilled person to stay in the sun 15 times longer. In other words, SPF 15 means that 1 / 15 of the burning UV radiation will reach the skin, assuming sunscreen is applied evenly at a thick dosage of 2 milligrams per square centimeter (mg / cm2).

[0077] The term “biodegradation” as used herein denotes that microorganism metabolize the material completely to CO2, energy, water, and biomass in an aerobic process (according to OECD guideline). If not indicated otherwise, biodegradability is assessed herein according to OECD 301 F over a time period of 28 days at 22°C. As used herein, biodegradable includes “partially biodegradable” and “readily biodegradable”. As used herein, if a compound of formula (I) or an organic component of the composition is “partially biodegradable”, this means having a biodegradability of equal to or more than 20% (>20%) but less than 60% (<60%). In particular, partially biodegradable as used herein is defined as >20% but <60% biodegradability as measured by OECD 301 F (BASF screening test) testing. As used herein, if a compound of formula (1) or an organic component of the composition is “readily biodegradable”, this means having a biodegradability of larger or equal to 60% (>60%). In particular, readily biodegradable as used herein is defined as >60% biodegradability as measured by OECD 301 F (BASF screening test) testing.

[0078] In general, the biodegradability of an organic component can be assessed via different OECD 301 A-F measurements. With regard to the present invention it is to be understood that the biodegradability has been assessed for compounds of formula (I) according to a measurement of the OECD 301 F testing method defined throughout the present application as OECD 301 F (BASF screening test). The procedure of the OECD 301 F and OECD 301 F (BASF screening test) are described as follows:

[0079] For the principle of the OECD 301 F test reference is made to the OECD Guidelines for the Testing of Chemicals, Section 3, Environmental fate and behavior (doi.org / 10.1787 / 2074577x). A measured volume of inoculated mineral medium, containing a known concentration of test substance (100 mg test substance / L giving at least 50-100 mg ThOD / l; ThOD = theoretical oxygen demand) as the nominal sole source of organic carbon, is stirred in a closed flask at a constant temperature for up to 28 days. The consumption of oxygen is determined either by measuring the quantity of oxygen (produced electrolytically) required to maintain constant gas volume in the respirometer flask, or from the change in volume or pressure (or a combination of the two) in the apparatus. Evolved carbon dioxide is absorbed in a solution of potassium hydroxide or another suitable absorbent. The amount of oxygen taken up by the microbial population during biodegradation of the test substance (corrected for uptake by blank inoculum, run in parallel) is expressed as a percentage of ThOD or, less satisfactorily, COD. ThOD describes the theoretical oxygen demand and COD describes the common oxygen demand.

[0080] OECD 301 F (BASF screening test): Biodegradation in wastewater was tested in triplicate using the OECD 301 F manometric respirometry method. OECD 301 F is an aerobic test that measures biodegradation of a sample by measuring the consumption of oxygen. To a measured volume of medium, 100 mg / L test substance, which is the nominal sole source of carbon is added along with the inoculum (aerated sludge taken from Mannheim waste water treatment plant). This is stirred in a closed flask at a constant temperature of 22 °C for 28 days. The consumption of oxygen is determined by measuring the change in pressure in the apparatus using an OxiTopC. Evolved carbon dioxide is absorbed in a solution of sodium hydroxide. Nitrification inhibitors are added to the flask to prevent usage of oxygen due to nitrification. The amount of oxygen taken up by the microbial population during biodegradation of the test substance (corrected for uptake by blank inoculum, run in parallel) is expressed as a percentage of ThOD (theoretical oxygen demand, which is measured by the elemental analysis of the compound). A positive control Glucose / Glucosamine is run along with the test samples for each cabinet.

[0081] Biodegradation can then be calculated according to the following formula according to the OECD Guideline for the Testing of Chemicals, Section 3

[0082] BOD = (mg O2 uptake by test substance - mg O2 uptake by blank) / mg test substance in vessel % degradation is calculated according to the following formula according to the OECD Guidelines for the Testing of Chemicals, Section 3:

[0083] % degradation = BOD / ThOD x 100

[0084] In this context, the term “organic component” as used above denotes any organic compound, i.e., any compound comprising organic carbon. In the context of the above, this refers to any carbon-containing compound except for the following carbon-containing compounds, which are considered inorganic compounds: carbides, carbonates (salts of carbonic acid characterized by the CCh2' anion, and thus not carbonate esters), bicarbonates (salts of carbonic acid characterized by the HCOs" anion), carbonic acid, CO, CO2, and inorganic cyanides (salts characterized by the CN_anion). Further, elemental forms of carbon, such as graphite, diamond, fullerenes, or carbon nanotubes, are not considered organic carbon. Further details of said method can be derived from the examples below.

[0085] In said OECD 301 F test, the sample may either be used as such, i.e. the compound material, or may be prepared by coating it on an inert substance, such as quartz sand. In the quartz sand sample preparation, the sample can be dissolved in acetone, and quartz sand is subsequently added. Acetone is evaporated while stirring to ensure the test substance is evenly applied to the quartz sand. This quartz sand / sample mixture is then utilized for the degradation test. Further details are as described in the examples below.

[0086] Various embodiments regarding the compound of formula (I) as well as the use of the compound of formula (I) to protect skin against UV radiations or as a light stabilizer are described hereinafter. It is to be understood that the preferred embodiments of the invention are preferred alone or in combination with each other. Further, preferred embodiments regarding the cosmetic or pharmaceutical composition comprising a compound of formula (I) as well as the use of such a cosmetic or pharmaceutical composition e.g. in sunscreens are described hereinafter.

[0087] The compounds of the invention are generally 2-cyano acrylic acid derivatives according to formula (I) or the salt, hydrate, tautomer or stereoisomer thereof; wherein

[0088] R1is -Phenyl-(OR4)

[0089] R2is H;

[0090] R3is selected from C2-C12 alkyl;

[0091] R4is -C(=O)R6; R6is C1-C4 alkyl.

[0092] The salts are preferably pharmaceutically or cosmetically acceptable salts. The stereoisomers are preferably E / Z isomers. In various embodiments, the E conformation shown in formula (I) is the preferred conformation.

[0093] In various embodiments, in the compound according to formula (I) R3is linear or branched C3-C12 alkyl, preferably C3-, C4-, C5-, Ce-, C7-, Cs-, C9-, or Cio-alkyl, for example C4-Cio-alkyl, such as Ce-Cg-alkyl, in particular Ce-Cs-alkyl, preferably Cs-alkyl, more preferably branched Cs-alkyl, most preferably 2-ethylhexyl.

[0094] In various embodiments, in the compound according to formula (I) R6is C1-C3 alkyl, preferably methyl or ethyl.

[0095] In various embodiments, in the compound according to formula (I) R3is linear or branched C3-C12 alkyl, preferably C3-, C4-, C5-, Ce-, C7-, Cs-, C9-, or Cio-alkyl, for example C4-Cio-alkyl, such as Ce-Cg-alkyl, in particular Ce-Cs-alkyl, preferably Cs-alkyl, more preferably branched Cs-alkyl, most preferably 2-ethylhexyl, and and R6is C1-C3 alkyl, preferably methyl or ethyl.

[0096] In one embodiment, the compound is a compound according to formula (I); wherein the compound is a compound of formula (la) or a salt, hydrate, tautomer or stereoisomer thereof:

[0097] In various embodiments, the compound has a biodegradability of at least 15%, at least 20%, at least 30%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70% degradation as determined over 28 days at 22°C according to OECD 301 F.

[0098] As indicated above, the present invention further relates to a composition, comprising at least one compound of formula (I) according to the present invention as described above. The composition may be a personal care, pharmaceutical or home care composition. Depending on the intended use, it may further comprise a dermatologically acceptable emulsifier, thickener, or emollient.

[0099] Preferably, the compound of formula (I) is present in the composition, in particular a pharmaceutical or personal care composition as described herein, in an amount of from 0.5 to 50 wt.-%, 1 to 45 wt.-%, 2 to 40 wt.-%, 2.5 to 35 wt.-%, 1 .0 to 20 wt.%, 1 .0 to 15 wt.-%, 1 .0 to 10.0 wt.-%, 1 .5 to 8 wt.-%, or 2.0 to 6.0 wt.-%, based on the total weight of the personal care or pharmaceutical composition. Lower concentration limits may be 0.5, 1 .0, or 1 .5 wt.-% and upper limits may be 50, 45, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 , 10, 9, 8, 7, ,6, 5 or 4 wt.-%. All amounts are given relative to the total weight of the composition. In various embodiments, the pharmaceutical or personal care compositions further comprise at least one further UV filter different to the compounds of formula (I).

[0100] This additional UV filter may be selected from organic and inorganic UV filters and may optionally be biodegradable, as defined above. In various embodiments, such additional UV filter is selected from inorganic UV filters. In various embodiments, it may be selected from organic UV filters. The additional UV filter may be a particulate or oil-soluble or water-soluble UV filter.

[0101] Water soluble UV filters have a solubility in water of at least 2 % by weight, preferably at least 3 % by weight, more preferably at least 5 % by weight. If no indicated otherwise, all solubilities given herein are at standard conditions, i.e. room temperature (25°C) and atmospheric pressure (1013 mbar).

[0102] “Oil soluble” UV filters or “UV filters soluble in at least one cosmetic oil” have a solubility in common cosmetic oils, such as Ci2-Ci5-alkyl benzoate, dibutyl adipate, diisopropyl sebacate, phenethyl benzoate, coco- caprylate ( / caprate), propylheptyl caprylate, caprylic / capric triglyceride, cocoglycerides, propylene glycol dicaprylate / dicaprate, butylene glycol dicaprylate / dicaprate, triethyl citrate, isopropyl myristate, isopropyl palmitate, lauryl lactate, phenox, ethyl caprylate isopropyl lauroyl sarcosinate or dicaprylyl carbonate of at least 2 % by weight, preferably at least 5 % by weight, more preferably at least 7 % by weight.

[0103] If a UV filter is defined as being “oil-soluble” or “soluble in at least one cosmetic oil” herein, this means that it has a solubility of at least 2% by weight in any one or more of the afore-mentioned cosmetic oils, i.e. in one or more of Ci2-Ci5-alkyl benzoate, dibutyl adipate, diisopropyl sebacate, phenethyl benzoate, coco- caprylate ( / caprate), propylheptyl caprylate, caprylic / capric triglyceride, cocoglycerides, propylene glycol dicaprylate / dicaprate, butylene glycol dicaprylate / dicaprate, triethyl citrate, isopropyl myristate, isopropyl palmitate, lauryl lactate, phenox, ethyl caprylate isopropyl lauroyl sarcosinate, and dicaprylyl carbonate. In some embodiments, it may have the given solubility in all of the listed cosmetic oils.

[0104] The term insoluble, particulate organic UV filter refers to UV filters that are not soluble in water and not in cosmetic oils. This may mean that their solubility in water and the cosmetic oils mentioned above is below 2 % by weight, for example below 1 % by weight.

[0105] As the at least one additional UV filter, UVA, UVB, and / or different broadband UV filters may be used. Suitable UV filters may be organic or inorganic, particulate or non-particulate. Non-particulate UV filters may be miscible or soluble in a given solvent, such as water or a cosmetic oil. In some instances, they may be water soluble or oil soluble, as herein defined. In contrast to non-particulate UV filters, the term “particulate UV filter” relates to UV filters that are essentially insoluble in water or (cosmetic) oils, i.e. their solubility in water and the cosmetic oils mentioned above is below 2 % by weight, for example below 1 % by weight. The term “organic particulate UV filter” relates to UV filters that can be micronized due to their low water and low oil solubility and are dispersed as a particle in water or in oil. “Non-particulate” thus means those filters that are oil- and / or water miscible or -soluble. Oil- and / or water-soluble filters as defined herein, i.e. are not present as solids in the compositions, but may be solids (as such, i.e. if not formulated with other compounds) at 25°C.

[0106] In various embodiments, the UV filters to be additionally comprised in the compositions defined herein are UV filters that are solid at 25 °C and / or are soluble in at least one cosmetic oil. In various embodiments, they are both, i.e. solid at 25°C and soluble in at least one cosmetic oil.

[0107] In various embodiments, the at least one additional UV filter comprised in the compositions of the invention comprises or is a non-particulate oil-soluble UV filter.

[0108] In various embodiments, the at least one additional UV filter comprised in the compositions of the invention comprises or is a non-particulate water-soluble UV filter.

[0109] In various embodiments, the at least one additional UV filter comprised in the compositions of the invention comprises or is a particulate UV filter.

[0110] The at least one additional UV filter comprises or is, in various embodiments, an organic UV filter.

[0111] In various embodiments, the at least one additional UV filter comprises an organic, solid and oil-soluble UV filter. In various alternative or cumulative embodiments, the at least one additional UV filter comprises an organic, solid and particulate UV filter.

[0112] The compositions of the invention may comprise any one or more of the above types of additional UV filter either individually or in combination.

[0113] Suitable UVA filters may be selected from the group consisting of disodium phenyl dibenzimidazole tetrasulfonate, hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate), 1-(4-(1 ,1-dimethylethyl)phenyl)-3-(4-methoxyphenyl)propane-1 ,3-dione (INCI butyl methoxydibenzoylmethane, also known as avobenzone), terephthalylidene dicamphor sulfonic acid (TDSA), methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate (MCE), and combinations thereof.

[0114] Suitable UVB filters may be selected from the group consisting of 4,4',4"-(1 ,3,5-triazine-2,4,6- triyltriimino)tris-benzoic acid-tris(2-ethylhexyl)ester (INCI ethylhexyl triazone), 4,4'-[[6-[[4-[[(1 , 1 - dimethylethyl)amino]carbonyl]phenyl]amino]-1 ,3,5-triazin-2,4-diyl]diimino]bis-benzoic acid-bis(2- ethylhexyl)ester (INCI diethylhexyl butamido triazone), phenylbenzimidazole sulfonic acid, and combinations thereof.

[0115] Suitable broadband UV filters may be selected from the group consisting of bis-ethylhexyloxyphenol methoxyphenyl triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine), 2-(2H-benzotriazol-2-yl)-6- [(2-ethylhexyloxy)methyl]-4-methylphenol, 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1 ,3,3,3- tetramethyl-1-[(trimethylsilyl)oxy]-1-disiloxanyl]propyl]phenol (INCI drometrizole trisiloxane), 2,2'- methylenbis[6-(2H-benzotriazol-2-yl)-4-(1 ,1 ,3,3-tetramethylbutyl)phenol] (INCI methylene Bis- benzotriazolyl tetramethylbutylphenol), phenylene bis-diphenyltriazine (PBDT), benzophenone-3 and combinations thereof.

[0116] Suitable organic particulate UV filters ( / .e., insoluble, organic UV filters) may be selected from the group consisting of 2,2'-methylene bis[6-(2H-benzotriazol-2-yl)-4-(1 ,1 ,3,3-tetramethylbutyl)phenol] (INCI methylene bis-benzotriazolyl tetramethylbutylphenol), 2,4,6-tris(biphenyl-4-yl)-1 ,3,5-triazine (INCI trisbiphenyl triazine), 1 ,1 ’-(1 ,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]- methanone (INCI bis-(diethylaminohydroxybenzoyl benzoyl) piperazine), 5,6,5’,6’-tetraphenyl-3-3’-(1 ,4- phenylene)bis(1 ,2,4-triazine) (INCI phenylene bis-diphenyltriazine; PBDT), 1 ,4-di(benzoxazole-2'- yl)benzene and combinations thereof. Further examples of suitable organic particulate UV filters are described e.g. in WO9703643, W02009077356 and WO2015155158. Preferably, the particulate UV filters have a particle size DN50 determined by light scattering of less than 2000 nm, preferably less than 1000 nm, wherein DN50 refers to the particle size value, where half of the population lies below this value, and half of the population lies above this value, i.e., the median value of the particle size volume distribution.

[0117] Inorganic UV filters include titanium dioxide, zinc oxide, iron oxide, cerium oxide and mixtures thereof. In various embodiments, the inorganic UV filters may be applied as a nano material. In this connection it is to be understood that the term “nano material” follows the recommendation of the European Commission 2011 / 696 / EU. Accordingly, in a nano material 50 % of particles, based on a number-based size distribution, are smaller than 100 nm, including constituent particles in aggregates or agglomerates. In another embodiment of the present invention, the inorganic UV filters may be applied as a non-nano material. Accordingly, in a non-nano material more than 50 % of the particles, based on a number-based size distribution, are larger than 100 nm. It is also possible to use mixtures of nano and non-nano inorganic UV filters. Furthermore, the inorganic UV filters may be coated or uncoated. If present, titanium dioxide is preferably coated, as uncoated titanium dioxide is photocatalytic and should be avoided in sunscreens. Coatings suitable in the context of inorganic UV filters may be organic and / or inorganic and are, for instance, disclosed in WO 2023 / 036749 A1 .

[0118] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT).

[0119] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), diethylamino hydroxy benzoyl hexyl benzoate (DHHB).

[0120] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), butyl methoxydibenzoylmethane (BMDBM).

[0121] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), ethylhexyl triazone (EHT). In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), methylene bis-benzotriazolyl tetramethylbutylphenol (MBBT).

[0122] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), tris-biphenyl triazine (TBPT).

[0123] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate (MCE).

[0124] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), zinc oxide.

[0125] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), titanium dioxide.

[0126] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), cerium oxide.

[0127] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), iron oxide.

[0128] In various embodiments, the composition is free of octocrylene.

[0129] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one UVA filter, such as DHHB or BMDBM or MCE, and at least one UVB filter, such as EHT.

[0130] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one broadband UV filter, such as BEMT, and at least one UVA filter, such as DHHB or BMDBM or MCE.

[0131] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one broadband UV filter, such as BEMT, and at least one UVB filter, such as EHT.

[0132] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one broadband UV filter, such as BEMT, and at least one UVA filter, such as DHHB or BMDBM or MCE, and at least one UVB filter, such as EHT.

[0133] In various embodiments, the composition comprises at least one broadband UV filter, such as BEMT, and at least one UVA filter, such as DHHB, and at least one UVB filter, such as EHT.

[0134] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one particulate UV filter, such as MBBT, PBDT or TBPT, and at least one UVA filter, UVB filter and / or broadband UV filter, such as any one or more of DHHB, BMDBM, MCE, EHT, and BEMT. The composition may thus comprise combinations of MBBT and BEMT, MBBT and EHT, and MBBT and DHHB or BMDBM or MCE. Further, a particulate UV filter, such as MBBT, may be used in combination with any combination of UVA, UVB and broadband UV filters disclosed in various embodiments above.

[0135] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one broadband UV filter, such as BEMT, preferably in an amount of from 0.5 to 10 % by weight, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1 .0, 1 .5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6, 7, 8, 9, or 10 wt.-%, more preferably in an amount of from 2 to 5 % by weight, based on the total weight of the sunscreen or daily care composition.

[0136] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one UVA filter, such as DHHB or BMDBM or MCE, preferably in an amount of from 0.5 to 10 % by weight, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1 .0, 1 .5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6, 7, 8, 9, or 10 wt.-%, based on the total weight of the sunscreen or daily care composition.

[0137] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one UVB filter, such as EHT, preferably in an amount of from 0.5 to 10 % by weight, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1 .0, 1 .5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6, 7, 8, 9, or 10 wt.-%, based on the total weight of the sunscreen or daily care composition.

[0138] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one particulate UV filter, such as MBBT, PBDT, or TBPT, preferably in an amount of from 0.5 to 10 % by weight, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1 .0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6, 7, 8, 9, or 10 wt.-%, based on the total weight of the sunscreen or daily care composition.

[0139] In various embodiments, the weight ratio of the at least one broadband UV filter to at least one UVB filter, at least one UVA filter or at least one particulate UV filter may be in the range of 1 :5 to 5:1 , for example 1 :3 to 3:1.

[0140] In various embodiments, the weight ratio of the at least one UVA filter to at least one UVB filter or at least one particulate UV filter may be in the range of 1 :5 to 5:1 , for example 1 :3 to 3:1 .

[0141] In various embodiments, the weight ratio of the at least one UVB filter to at least one particulate UV filter may be in the range of 1 :5 to 5:1 , for example 1 :3 to 3:1 .

[0142] In various embodiments, the weight ratio of the at least one particulate UV filter to at least one UVB filter or at least one UVA filter may be in the range of 1 :5 to 5:1 , for example 1 :3 to 3:1 .

[0143] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), ethylhexyl methoxycinnamate. In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), ethylhexyl salicylate.

[0144] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), homosalate.

[0145] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), amiloxate.

[0146] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), padimate O.

[0147] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), shinorine.

[0148] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), gadusol.

[0149] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), mycosporine-2 glycine.

[0150] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), porphyra-334.

[0151] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), a UV filter from the group of cyanoacrylates, the cyanoacrylates optionally being any one or more of

[0152] In various embodiments, the composition comprises, in addition to the at least one UV filter of formula (I), at least one compound selected from those listed in the following table:

[0153] All documents cited herein above in relation to the additional UV filters that may be included in the compositions of the invention, are herewith incorporated by reference in their entirety. In one embodiment of the present invention, the composition further comprises at least two additional UV filters, different to the compound of formula (I). These may be selected from those described above. In various embodiments, the additional UV filter may be a natural and / or biodegradable UV filter. “Natural”, as used in this context, refers to compounds that occur in nature and are thus naturally occurring compounds in contrast to those that are artificially produced. “Biodegradable”, as used in this context, refers to compounds that are biodegradable as defined herein above.

[0154] In various embodiments, the composition comprises a total of 5 to 40 wt.-%, such as 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, or 40 wt.-% of UV filters, preferably of 8 to 35 wt.-%, more preferably of 9 to 30 wt.-% or of 9 to 35 wt.-%, still more preferably of 9 to 25 wt.-%, and in particular of 9 to 20 wt.-%, based on the total weight of the sunscreen or daily care composition.

[0155] In one embodiment of the present invention, the composition according to the present invention further comprising a photostabilizer. Photostabilizers may be used in a quantity sufficient to obtain a substantial and significant improvement in the photostability of the composition containing a compound of formula (I). This minimum quantity of photostabilizer to be used may vary depending on the starting quantity of compound of formula (I) present in the composition and depending on the nature of the dermatologically acceptable support used in the composition. It may be determined without difficulty using a conventional photostability measuring test.

[0156] In various embodiments, the photostabilizer is present in the composition in an amount of at least 0.5 wt.- %, preferably at least 1 wt.-%, more preferably at least 2 wt.-%, and in particular at least 4 wt.-%, based on the total weight of the composition. In another preferred embodiment, the photostabilizer is present in the composition in an amount of from 0.5 to 15 wt.-%, preferably from 1 to 12 wt.-%, more preferably from 2 to 10 wt.-%, and in particular from 4 to 8 wt.-%, based on the total weight of the composition.

[0157] In various embodiments, the photostabilizer is a quencher. The quencher may be present in the composition in an amount of at least 0.5 wt.-%, preferably at least 1 wt.-%, more preferably at least 1.5 wt.-%, and in particular at least 2 wt.-%, based on the total weight of the composition. In another embodiment, the quencher is present in the composition in an amount of from 0.5 to 10 wt.-%, preferably from 1 to 8 wt.-%, more preferably from 1 .5 to 6 wt.-%, and in particular from 2 to 5 wt.-%, based on the total weight of the composition.

[0158] In a preferred embodiment of the present invention, the photostabilizer is selected from the group consisting of

[0159] • CAS-Regno. 444811-29-4, Propanedioic acid, [(4-hydroxy-3,5-dimethoxyphenyl)methylene]-, bis(2- ethylhexyl) ester (Oxynex ST)

[0160] • CAS-Regno. 477844-93-2, Octofluorene

[0161] • 2-phenylethylbenzoate

[0162] • CAS-Regno. 127474-91-3, 2,6-Naphthalenedicarboxylic acid, bis(2-ethylhexyl) ester (Hallbrite TQ,

[0163] Corapan TQ)

[0164] • ethylhexyl methoxycrylene polyester-8 diethylhexyl syringylidenemalonate trimethoxybenzylidene pentanedione

[0165] Bis(Cyano Butylacetate) Anthracenediylidene polyester-25 butyloctyl salicylate

[0166] CAS-Regno. 68890-66-4, Octopirox

[0167] Tinogard TT (INCI Tetradibutyl Pentaerithrityl Hydroxy- hydrocinnamate)

[0168] Tinogard HS (INCI Sodium Benzotriazolyl Butylphenol Sulfonate)

[0169] Tinogard TL (INCI Benzotriazolyl Dodecyl p-Cresol)

[0170] Phenol, 2-(2H-benzotriazol-2-yl)-6-dodecyl-4-methyl-, branched and linear

[0171] Cibafast H Liquid (INCI Sodium Benzotriazolyl Butylphenol Sulfonate, Buteth-3, Tributyl Citrate)

[0172] Tinogard AS (INCI Bumetrizole)

[0173] Tris(tetramethylhydroxypiperidinol) citrate (Tinogard Q)

[0174] Piperidinol, 1 -hydroxy-2, 2, 6, 6-tetramethyl-, 2-hydroxy-1 ,2,3-propanetricarboxylate (3:1) (salt)

[0175] CAS-Regno. 1750-49-8, N-(2-Hydroxypropyl)urea

[0176] CAS-Regno. 2078-71-9, N-(2-Hydroxyethyl)urea mixture of n-butylphthalimide and isopropylphthalimide

[0177] CAS-Regno. 872424-70-9

[0178] CAS-Regno. 872424-71-0

[0179] CAS-Regno. 872424-72-1

[0180] CAS-Regno. 872424-73-2

[0181] CAS-Regno.6197-30-4, Octocrylene

[0182] CAS-Regno. 118-60-5, 2-Ethylhexyl salicylate

[0183] CAS-Regno. 180898-37-7, Disodium phenyldibenzimidazoletetrasulfonate Neo Heliopan AP or Neo- Heliopan APC

[0184] CAS-Regno. 302776-68-7, Uvinul A Plus

[0185] CAS-Regno.70356-09-1 , 4-tert-Butyl-4'-methoxydibenzoylmethane (Avobenzone)

[0186] Tinosorb M (micronized CAS-Regno. 103597-45-1)

[0187] Tinosorb S (CAS-Regno. 187393-00-6)

[0188] CAS-Regno. 88122-99-0, Ethylhexyl triazone (Octyl triazone; Uvinul T 150)

[0189] CAS-Regno. 154702-15-5, Diethylhexyl butamidotriazone (Uvasorb HEB)

[0190] CAS-Regno. 155633-54-8, Drometrizole trisiloxane (Mexoryl XL), and

[0191] • CAS-Regno. 92761-26-7 Mexoryl SX; Terephthalylidene-3,3'-dicamphor-10,10'-disulfonic acid

[0192] Specific examples include triplet quenchers, such as Tinogard Q (comprising tris(tetramethylhydroxypiperidinol) citrate (also known as 4-Piperidinol, 1 -hydroxy-2, 2, 6, 6-tetramethyl-, 2- hydroxy-1 ,2,3-propanetricarboxylate (3:1) (salt) or CAS-Regno. 220410-74-2), water (CAS-Regno. 7732- 18-5) and ethanol (CAS-Regno. 64-17-5)). Tinogard Q is an Excited State Quencher, water soluble and is delivered in liquid formulation. Excited State Quencher helps to prevent light induced degradation of formulations in transparent packagings. In combination with UV absorbers it results in highly effective stabilizer systems. In general, Tinogard Q is used to protect personal care products from degradation caused by exposure to UV radiation in transparent packaging. It is applied in e.g. body wash, face wash, liquid hand soap, skin care, shampoo, hair conditioner, and fragrances.

[0193] In various embodiments, the compositions can additionally comprise one or more further biodegradable compounds, including those selected from the group consisting of C12-C15 alkyl benzoates, coco glycerides, coconut oil, dibutyl adipate, dodecyl lactate, ethylhexyl benzoate, glycerol, glyceryl stearate, lauryl glycoside, lauryl lactate, triglycerides, phenoxyethanol, phenoxy ethyl caprylate, polyglyceryl-2- dipolyhydroxy-stearate, stearoyl glutamate and salts thereof, stearyl alcohol, dicarboxymethyl alaninate and salts thereof, and xanthan gum as well as combinations thereof. The salts of the afore-mentioned compounds may be the alkaline metal salts, for example the sodium salts.

[0194] In some embodiments, the composition is free of at least one or more of parabenes and octocrylene. In some embodiments, the composition is free of parabens. In various embodiments, the composition is free of octocrylene. In various embodiments, the composition is free of parabenes and octocrylene.

[0195] In various embodiments, the composition, for example a sunscreen or daily care composition with photoprotection, provides a SPF of more than 15, preferably of more than 30. In another preferred embodiment of the present invention, the composition provides a SPF of more than 50, preferably of more than 60. In another preferred embodiment of the present invention, the composition provides a SPF of more than 90. The SPF may be determined according to any method known in the art.

[0196] Further, in connection with the above embodiments, it is to be understood that the compositions may comprise at least one further additive.

[0197] In one embodiment, the at least one additive is selected from the group consisting of cosmetic oils, emulsifiers, emollients, viscosity regulators (thickeners), stabilizers, sensory enhancers, humectants, film formers, UV scattering compounds, UV boosters, pH adjusters, adjuvants such as vitamins, antioxidants, chelating agents, preservatives, perfumes, and combinations thereof, including those mentioned above as being biodegradable.

[0198] Exemplary cosmetic oils include, without limitation, Ci2-Ci5-alkyl benzoate, dibutyl adipate, diisopropyl sebacate, phenethyl benzoate, coco-caprylate ( / caprate), propylheptyl caprylate, caprylic / capric triglyceride, cocoglycerides, propylene glycol dicaprylate / dicaprate, butylene glycol dicaprylate / dicaprate, triethyl citrate, isopropyl myristate, isopropyl palmitate, phenox, ethyl caprylate isopropyl lauroyl sarcosinate, and dicaprylyl carbonate

[0199] Exemplary O / W emulsifiers include, without limitation, glucose derivatives such as cetearyl glucoside, arachidyl glucoside, lauryl glucoside, polyglyceryl-3 methylglucose distearate, methyl glucose sesquistearate; sucrose derivative such as sucrose polystearate, sucrose palmitate; sorbitol derivatives such as polysorbate derivatives; inulin derivatives such as inulin lauryl carbamate; glycerides of fatty acids such as glyceryl stearate, glyceryl stearate SE, glyceryl stearate citrate, glutamic acid derivatives such as sodium stearoyl glutamate; sulfosuccinic acid derivatives such as disodium cetearyl sulfosuccinate; phosphoric acid derivatives such as potassium cetyl phosphate, ceteh-10 phosphate, C20-22 alkyl phosphate; fatty acid esters of polyglyceryl such as polyglyceryl-3-diisostearate, polyglyceryl-2- dipolyhydroxystearate; polyglyceryl-10 stearate oxyalkenylated fatty alcohol such as ceteareth-20, steareth-21 , beneheth-25 oxyalkenylated fatty acid such as PEG-100 stearate oxyalkenylated organomodified silicone I polysiloxane I polyalkyl I polyether copolymers and derivatives. ethoxylated fatty acid soap phospholipids based such as lecithin derivatives

[0200] Exemplary emulsifiers to form a W / O emulsion include, without limitation, glycerides of fatty acids such glyceryl oleate, sorbitan laurate sorbitan esters such as sorbitan oleate fatty acid esters of polyglyceryl such as polyglyceryl-3-diisostearate, polyglyceryl-2- dipolyhydroxystearate, polyglyceryl-4 isostearate

[0201] Oxyalkenylated fatty alcohol such steareth-2

[0202] Oxyalkenylated fatty acid such as PEG-30 dipolyhydroxystearate organomodified silicone I polysiloxane I polyalkyl I polyether copolymers and derivatives such as cetyl dimethicone copolyol, cetyl PEG / PPG-10 / 1 Dimethicone, PEG-10 dimethicone

[0203] Exemplary emollients include, without limitation, esters of linear or branched fatty acids with linear or branched fatty alcohols such as propylheptyl caprylate, coco caprylate, isopropyl myristate, ethylhexyl palmitate; esters of aromatic carboxylic acids with linear or branched fatty alcohols such as C12-C15-alkyl benzoate, ethylhexyl benzoate, phenethyl benzoate; dicarboxylic acid esters with linear or branched alcohols such as dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate; esters of hydroxycarboxylic acids with linear or branched fatty alcohols; esters of linear or branched fatty acids with polyhydric alcohol such as butylene glycol dicaprylate / dicaprate; mono-, di-, tri-glycerides based on C6-C18 fatty acids such as caprylic I capric triglycerides, coco glycerides; guerbet alcohols such as octyldodecynol; hydrocarbons such as hydrogenated polyisobutene, mineral oil, squalene, isohexadecane; ethers such as dicaprylyl ether; silicone derivatives (organomodified polysiloxanes) such as dimethylpolysiloxane, cyclic silicones.

[0204] Exemplary lipophilic thickeners include, without limitation, fatty alcohols such as cetyl alcohol, cetearyl alcohol, stearyl alcohol; behenyl alcohol fatty acids such as stearic acid; palmitic acid fatty acid esters such as myristyl stearate, pentaerythrityl distearate, cetyl palmitate; Tribehenin, dextrin palmitate waxes such as beeswax, carnauba wax, microcrystalline wax, ceresin, ozocerite; Oryza Sativa bran wax, sunflower wax hydrogenated vegetable oil, hydrogenated castor oil, hydrogenated vegetable glycerides, hydrogenated castor oil / sebacic acid copolymer silica based derivatives such as silica, silica dimethyl silylate.

[0205] Hydrophilic stabilizers / thickeners include, without limitation, natural gums such as xanthan gum, tara gum, carrageenan, guar gum, agar gum, alginates, gellan gum silicate derivatives such as magnesium aluminum silicates; cellulose derivatives such as hydroxypropyl cellulose, microcrystalline cellulose starch derivatives such as hydroxypropyl starch phosphate polyacrylates or homopolymers of reticulated acrylic acids or polyacrylamides such as carbomers, acrylate copolymers, acrylate I C10-C30-alkyl acrylate crosspolymer, acrylate I beheneth-25 methacrylate copolymer

[0206] Also included may be UV protection scattering compounds. These include, without limitation: microcrystalline cellulose; calcium carbonate; hydroxyapatite; silica. hollow sphere such as Styrene / Acrylates Copolymer

[0207] Further components may belong to the class of film formers and film forming enhancers. Such compounds include, without limitation, hydrogenated dimer dilinoleyl / dimethylcarbonate copolymer; diisostearoyl polyglyceryl-3 dimer dilinoleate; polyglyceryl-3 stearate / sebacate crosspolymer; cellulose derivatives, such as methylcellulose and ethylcellulose; capryloyl glycerin / sebacic acid copolymer.

[0208] Exemplary sensory enhancers include, without limitation, polyamide derivatives such as nylon-12; polymethyl methacrylates; silica; mica; polymethylsilsesquioxane; polyethylene; starch derivatives such as aluminum starch octenylsuccinate; dimethicone derivatives; boron nitride;

[0209] HDI / trimethylol hexyllactone crosspolymer; perlite.

[0210] Exemplary humectants include, without limitation, polyols such as: glycerin; butylene glycol; propylene glycol; sorbitol beta-glucan;

[0211] 1 ,2 pentadiol;

[0212] 1 ,2 hexandiol;

[0213] 1 ,2 octandiol;

[0214] 1 ,2 decandiol;

[0215] 2-Methyl-1 ,3-propandiol.

[0216] Exemplary adjuvants include, without limitation, ethanol dyes pigments such as iron oxides tocopherol derivatives; retinol derivatives; ascorbic acid derivatives; bisabolol; allantoin; panthenol; chelating agents (EDTA, EDDS, EGTA, phytic acid, piroctone olamine); ethylhexyl glycerin; hydroxyacetophenone; caprylhydroxymic acid; propellants such as propane, butane, isobutene, dimethyl ether; styrene I PVP or styrene acrylamide copolymers; insect repellants such as butylacetylaminopropionate.

[0217] Exemplary preservatives include, without limitation, benzyl alcohol; zingerone. Exemplary perfumes include, without limitation, those selected from the group consisting of limonene, citral, linalool, alpha-isomethylionon, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyrane, 2-tert.- pentylcyclohexylacetate, 3-methyl-5-phenyl-1 -pentanol, 7-acetyl-1 ,1 ,3,4,4,6-hexamethyltetraline, adipine acid diester, alpha-amylcinnamaldehyde, alpha-methylionon, amyl C butylphenylmehtylpropionalcinnamal, amylsalicylate, amylcinnamylalcohol, anisalcohol, benzoin, benzylalcohol, benzylbenzoate, benzylcinnamate, benzylsalicylate, bergamot oil, bitter orange oil, butylphenylmethylpropioal, cardamom oil, cedrol, cinnamal, cinnamylalcohol, citronnellylmethylcrotonate, lemon oil, coumarin, diethylsuccinate, ethyllinalool, eugenol, evernia furfuracea extracte, evernia prunastri extracte, farensol, guajak wood oil, hexylcinnamal, hexylcalicylate, hydroxycitronellal, lavender oil, lemon oil, linaylacetate, mandarine oil, menthyl PCA, methylheptenone, nutmeg oil, rosemary oil, sweet orange oil, terpineol, tonka bean oil, triethylcitrate, vanillin and combinations thereof.

[0218] In connection with the above preferred embodiments, it is to be understood that if the composition comprises two or more additives, combinations of the additives as defined above are also part of the invention.

[0219] The final formulations of the compositions may exist in a wide variety of presentation forms, for example: in the form of liquid preparations as a W / O, O / W, oil-in-water-in-oil (O / W / O), water-in-oil-in water (W / O / W), a bi-phasic formulation or phase-inversion-technology (PIT) emulsion, a polymeric-based emulsion, and all kinds of microemulsions. The final formulations can be provided in different forms such as a gel, a cream, milk or lotion, in the form of a powder, in the form of a stick, in the form of a spray (spray with propellant gas or pump-action spray) or an aerosol, in the form of a foam, or in the form of a paste.

[0220] Typically, composition may comprise water in an amount of more than 5 % by weight, such as within the range of about 5.5 to 95 wt.-%, such as within the range of 10 to 90 wt.-%, for instance within the range of 15 to 85 wt.-%, based on the total weight of the composition.

[0221] For instance, when formulated as a water-in oil or an oil-in-water dispersion, an optional cosmetically acceptable carrier preferably comprises 5 to 50 % of an oil phase, 1 to 10 % of an emulsifier and 30 to 90 % of water, each by weight based on the total weight of the carrier. The oil phase may comprise any oil conventionally used in cosmetic formulations.

[0222] In connection with the above embodiments, it is to be understood that the compositions disclosed herein, in particular the sunscreen or daily care compositions, are particularly suitable for protection of the skin from UV radiation.

[0223] Hence, the present invention further relates to the composition, as defined herein, for use in protecting the human skin from UV radiation. The present invention further relates to a method of protecting the human skin from UV radiation by administration of the composition, such as the sunscreen or daily care composition, as defined herein. The invention is further directed to the use of the compounds described herein above, namely those of formula (I), to as an organic UV filter in a pharmaceutical, personal care or home care composition.

[0224] Also encompassed is the use of these compounds as a light stabilizer to protect ingredients against photolytic degradation.

[0225] The invention thus also features methods for protecting ingredients of a composition against photolytic degradation by adding a compound of formula (I) to said composition.

[0226] It is to be understood that the above embodiments of the compounds and compositions are also applicable for the uses and methods according to the present invention, and vice versa.

[0227] The present invention is further illustrated by the following non-limiting examples.

[0228] Examples

[0229] Compound 17 is according to the invention. All other compounds are comparative examples.

[0230] General procedure A

[0231] Ethylcyanoacetate 11 (1 ,2eq) and potassium fluoride (0.2eq) were dissolved in ethanol abs. (0.5M solution). The aldehyde 10 (1 eq) was added at such a rate that the temperature remained below 30°C. Afterwards, the mixture was heated to 50°C until TLC monitoring showed no more aldehyde (typically three hours to overnight). The mixture was then concentrated in vacuo to about a quarter of its original volume, poured in a mixture of ice and water (four times the volume of the obtained crystal slurry) and stirred for an hour. The product 12 was filtered off, washed with ethanol and water und dried in vacuo. Isolated yields were generally

[0232] > 90%.

[0233] General procedure B (transesterification)

[0234] 12 was dissolved in 10-20 eq of the respective alcohol 14, a catalytical amount of tetraethyl orthotitanate (typically 0.01 - 0.02 eq) was added and then refluxed until TLC analysis showed no more progress in the reaction (12 to 72 hours). The reaction mixture was evaporated in vacuo and the residue purified by column chromatography using toluene I ethyl acetate as eluent. The obtained product could be further purified by recrystallisation. Yields of 13 were generally in the range of 60-80%.

[0235] General procedure C (acylation)

[0236] The phenol 15 (1 eq) was dissolved in dichloromethane (1 M solution), pyridine (1.3eq) was added and the solution cooled in an ice bath. Acetyl chloride 16 (1 ,2eq) was added dropwise and the mixture was allowed to warm to ambient temperature overnight. The reaction mixture was poured in a mixture of ice and diluted hydrochloric acid and extracted with ethyl acetate following standard procedures. The combined organic phases were dried over sodium sulfate and concentrated in vacuo. The obtained product 12 generally solidified on standing and could be purified by recrystallisation. Typical yields were >90%.

[0237] NMR data of synthesized compounds according to general procedures

[0238] Compound numbering according to Table 1 below.

[0239] 36

[0240] 1 H-NMR 400MHz, CDCI3: 0.98, tr, 3H, CH(CH3)CH2CH3. 1.34, d, 3H, OCH(CH3); 1.72, m, 2H, OCH(CH3)CH2CH3; 2.32, s, 3H, CH3COO; 5.04, m, 1 H, COOCH , 7.24 and 8.02, 2 x d, 2H each, Ar; 8.20, s, 1 H, ArCH=C(CN)COO

[0241] 13C NMR 100MHz, DMSO: 14.5, CH2CH3; 62.4, CH2CH3; 97.5, CH; 116.8, Ar; 122.5, CN; 134.4, Ar, 156.1 , CH=C(R)-CN; 163.0, 163.4, Ar + CO

[0242] 16

[0243] 1 H NMR, 400 MHz, CDCI3: 0.86 - 1.01 , m, 6H, 2 x CH3; 1 .25 - 1 .51 , m, 8H, 4 x CH2; 1 .73, m, 1 H, CH, 4.25, q, 2H, O-CH2; 7.02, d, 2H, Ar; 7.20, s, 1 H, Ar-OH; 7.96, d, 2H, Ar; 8.21 , s, 1 H, CH

[0244] 13C NMR 100MHz, CDCI3: 11.0, 14.0, 2 x CH3; 22.9, 23.8, 28.9, 30.4, 4 x CH2; 38.8, O-CH2-CH; 69.1 , O-CH2; 98.7, C=CH; 116.1 , 116.5, 2 x Ar; 124.0, CN; 134.0, Ar, 145.4, C=C(R)-CN, 161.5, 163.4, Ar + CO.

[0245] 17

[0246] 1 H NMR, 400 MHz, CDCI3: 0.84 - 0.99, 6H, 2 x CH3; 1 .20 - 1 .50, m, 8H, 4 x CH2; 1 .69, m, 1 H, O-CH2- CH, 2.30, s, 3H, CH3CO, 4.21 , m, 2H, O-CH2-, 7.23, d, 2H, Ar; 8.01 , d, 2H, Ar; 8.18, S, 1 H, C=CH

[0247] 13C NMR 100MHz, CDCI3:11.0, 14.0, 2 CH3; 21 .1 , 22.9, 23.8, 28.8, 30.3, 4 x CH2 + CH3CO; 38.7, O- CH2CH; 69.0, O-CH2; 102.8, Ar-CH=; 115.2, 122.5, 2 x Ar; 129.0, CN, 132.5, Ar; 153.5, 154.3, Ar + C=C(R)-CN; 162.4; 168.6, 2 X COOR 29

[0248] 1 H NMR, 400 MHz, CDCI3: 1.33, d, 3H, CH3; 3.45 - 3.60, m, 2H, O-CH2-CH; 3.87, s, 3H, O-CH3; 5.25, m, 1 H, O-CH; 6.97, d, 2H, Ar; 7.97, d, 2H, Ar; 8.14, s, 1 H, C=CH

[0249] 13C NMR 100MHz, CDCI3:16.5, CH3; 55.6 O-CH(CH3); 59.2, O-CH2-CH; 71.8, 74.8, 2 x OCH3; 99.5, Ar- CH=C; 114.7, 116.1 , 2 x Ar; 124.3, CN; 133.6, Ar; 154.4 C=C(CN); 162.6, 163.8, Ar + CO

[0250] 34

[0251] 1 H NMR, 400 MHz, CDCI3: 0.98, tr, 3H, CH2CH3; 1.34, d, 3H, OCHCH3; 1.61 - 1.81 , m, 2H, CH-CH2- CH3; 3.89, s, 3H, OCH3; 5.03, m, 1 H, COOCH; 6.99, d, 2H, Ar; 8.00, d, 2H, Ar; 8.15, s, 1 H, Ar-CH=C

[0252] 13C NMR 100MHz, CDCI3: 9.6, CHCH3; 19.4, O-CH-CH3; 28.7, CH2-CH3, 55.6, O-CH; 74.9, O-CH3;

[0253] 99.8, CN; 114.6, Ar; 116.2, 124.4, Ar + Ar-CH; 133.6, Ar, 154.1 , 163.7, Ar + CO

[0254] 35

[0255] 1 H-NMR, 400MHz, CDCI3: 8.18, s, 1 H, C(CN)=CH; 8.00, 6.99, 2 x d, 2H each, aromatic H; 4.45, 4.06, 3.76, 3 x tr, 2H each, 3x OCH2; 3.60, q, 2H, OCH2CH3, 1 .80, m, 2H, ArOCH2CH2; 1 .51 , m, 2H, ArO(CH2)2-CH2; 1.23, tr, 3H, OCH2CH3; 0.99, tr, 3H, O(CH2)3-CH3

[0256] 6

[0257] Furfural (50.3g, 523 mmol), ethyl cyanoacetate (64.7g, 572 mmol) and ammonium acetate (3.2g, 42 mmol) were dissolved in xylene (mixture of isomers, 200g) and refluxed on a Dean-Stark-trap for 2.5 hours. The black solution was cooled to room temperature and the precipitated solid was filtered off, washed with a small quantity of xylene and dried in vacuo to yield 69.1g (69%) of 6 as reddish brown solid.

[0258] MP 90-92°C

[0259] 1 H-NMR (CDCI3, 400MHz): 1 .37, tr, 3H, CH3; 4.36, q, 2H, CH2; 6.66, dd, 1 H, Ar; 7.40, d, 1 H, Ar; 7.75, d, 1 H, Ar; 8.01 , s, 1 H, CH=C

[0260] 8

[0261] 6 (30.05g, 157mmol) was dissolved in 2-ethyl-1 -hexanol (206g, 1.58mol). Tetraethyl orthotitanate (0.1g, 0.4mmol) was added and the solution was stirred at 125° overnight. The resulting solution was cooled down and evaporated in vacuo. The crude product (44g) was purified by column chromatography using 20% ethyl acetate in heptane as eluent to yield 42g (97%) of 8 as waxy solid.

[0262] MP 34-36°C

[0263] 1 H-NMR (CDCI3, 400MHz): 0.77 - 0.93, m, 6H, 2 x CH3; 1.17 - 1 .45, m, 8H, 4 x CH2; 1 .57 - 1 .69, m, 1 H, CH; 4.15, m, 2H, COOCH2; 6.62, dd, 1 H, Ar; 7.36, d, 1 H, Ar; 7.70, d, 1 H, Ar; 7.94, s, 1 H, CH=C

[0264] 7

[0265] 7 was prepared analogously to 8 using 2-methyl-1 -butanol in place of 2-ethyl-1 -hexanol in quantitative yield as a brown oil. 1 H-NMR (CDCI3, 400MHz): 0.90, tr, 3H, CH3; 0.95, d, 3H, CH3; 1 .22 and 1 .45, 2 x m, 1 H each, CH2-CH3;

[0266] 4.02 - 4.17, m, 2H, COOCH2; 6.63, dd, 1 H, Ar; 7.36, d, 1 H, Ar; 7.72, d, 1 H, Ar; 7.96, s, 1 H, CH=C

[0267] 38

[0268] 38 was prepared analogously to 6 using 5-methylfurfural as aldehyde starting material. Quantitative yield as a yellow solid.

[0269] MP 65-70°C

[0270] I H-NMR (CDCI3, 400MHz):1 .37, tr, 2H, CH2CH3; 2.45, s, 3H, Ar-CH3; 4.33, q, 2H, OCH2; 6.31 , d, 1 H, Ar;

[0271] 7.30, d, 1 H, Ar; 7.91 , s, 1 H, CH=C

[0272] 11

[0273] I I was prepared analogously to 8 using 38 as starting material. Quantitative yield as a red oil.

[0274] 1 H-NMR (CDCI3, 400MHz): 0.81 - 0.96, m, 6H, 2 x CH3; 1 .23 - 1 .50, m, 8H, 4 x CH2, 1 .61 - 1 .74, m, 1 H, O-CH2-CH; 2.43, s, 3H, Ar-CH3; 4.18, q, 2H, O-CH2; 6.29, d, 1 H, Ar; 7.29, d, 1 H, Ar; 7.88, s, 1 H, CH=C

[0275] 2

[0276] 2 was synthesized from 1 , CAS 154786-36-4 using the general procedure B as described above. Yield 83% as light brown solid

[0277] MP 68-69°C

[0278] 1 H-NMR (CDCI3, 400MHz):0.93, tr, 3H, CH3; 0.99, d, 3H, CH3; 1 .26 and 1 .50, 2 x m, 1 H each, CH2-CH3; 1.84, m, 1 H, CH; 3.93, s, 6H, ArOCH3; 4.14, m, 2H, COOCH2; 6.31 , brs, 1 H, ArOH; 7.32, s, 2H, Ar; 8.09, s, 1 H, CH=C

[0279] 4

[0280] 4 was synthesized from 3, CAS 2601-03-8 using the general procedure B as described above. Quantitative yield as an orange oil.

[0281] 1 H-NMR (CDCI3, 400MHz): 0.90, tr, 3H, CH3; 0.95, d, 3H, CH3; 1 .23 and 1 .46, 2 x m, 1 H each, CH2CH3; 1.80, m, 1 H, CH; 3.85, s, 6H, 2 x OCH3; 3.99, s, 3H, OCH3; 4.10, m, 2H, OCH2; 7.23, s, 2H, Ar; 8.05, s, 1 H, CH=C

[0282] 9

[0283] 9 was synthesized from 39, CAS 10425-82-8 using the general procedure B as described above. 87% yield as yellow crystals.

[0284] MP 67-73°C

[0285] 1 H-NMR (CDCI3, 400MHz): 0.91 , tr, 3H, CH3; 1.30 - 1.41 , m, 4H, CH2-CH2-CH3; 1.41 - 1.51 , m, 2H, CH2, 1.77, quint., 2H, CH2, 3.12, tr, 2H, ring-CH2, 3.52, tr, 2H, ring-CH2; 4.27, m, 2H, OCH2; 7.40, tr, 1 H, Ar; 7.47, tr, 1 H, Ar; 7.54, tr, 1 H, Ar, 8.67, d, 1 H, Ar 26

[0286] 26 was synthesized from 39, CAS 10425-82-8 using the general procedure B as described above. 85% yield as yellow crystals.

[0287] MP 35-37°C

[0288] 1 H-NMR (CDCI3, 400MHz): 0.94, tr, 3H, CH3; 1 .01 , d, 3H, CH3; 1 .28 - 1 .52, 2 x m, 1 H each, CH2, 1 .83, m, 1 H, CH, 3.06, tr, 2H, ring-CH2, 3.45, tr, 2H, ring-CH2; 4.09, m, 2H, OCH2; 7.34, tr, 1 H, Ar; 7.42, d, 1 H, Ar; 7.49, tr, 1 H, Ar, 8.60, d, 1 H, Ar

[0289] 40

[0290] 40 was synthesized from 41 , CAS 91944-48-8 using general procedure A as described above. 90% yield as light-yellow solid.

[0291] MP 76-79°C

[0292] 1 H-NMR (CDCI3, 400MHz): 1.41 , tr, 3H, CH3; 1.48, s, 6H, C(CH3)2; 3.88-4.57, 5 x m, 1 H each, glycerol part; 4.39, q, 2H, COOCH2; 7.03, d, 2H, Ar; 8.01 , d, 2H, Ar; 8.18, s, 1 H, CH=C

[0293] 18

[0294] 18 was synthesized from 41 using the general procedure B as described above. 83% yield as a yellow solid MP 63-65°C

[0295] 1 H-NMR (CDCI3, 400MHz): 0.87 - 1 .02, m, 6H, 2 x CH3; 1 .28 - 1 .53, m, 14H, 4 x CH2 and C(CH3)2; 1 .72, m, 1 H, =CH2CH; 3.89-4.87, 6 x m, total of 7H, glycerol part and COOCH2; 7.03, d, 2H, Ar; 8.01 , d, 2H, Ar; 8.17, s, 1 H, CH=C

[0296] 42

[0297] To a solution of ethylene glycol monosalicylate (74.87g, 411 mmol) and triethylamine (89.7g, 886mmol) in dichloromethane (660ml) was added a solution of 2-cyanoacetyl chloride (47.5g, 445mmol) in dichloromethane (220ml) at a temperature of 0-5°C. The reaction was allowed to warm to room temperature overnight and then poured on ice. After extraction with ethyl acetate, 109g of crude product was obtained. Purification by column chromatography (15% ethyl acetate in toluene) yielded 45.5g, 44% of 42 as a yellow oil.

[0298] 1 H-NMR (CDCI3, 400MHz): 5.53, s, 2H, CH2CN; 4.97, 2 x tr, total of 4H, OCH2CH2O; 6.91 , tr, 1 H, Ar; 6.98, d, 1 H, Ar; 7.47, trd, 1 H, Ar; 7.84, dd, 1 H, Ar; 10.54, s, 1 H, ArOH

[0299] 15

[0300] 4-Methoxybenzaldehyde was reacted with 42 by using the general procedure A as described above. 15 was obtained in 79% yield as light-yellow crystals.

[0301] MP 122-124°C 1 H-NMR (CDCI3, 400MHz): 3.91 , s, 3H, OCH3; 4.67, s, 4H, OCH2CH2O; 6.91 , tr, 1 H, Ar; 7.01 , m, 3H, Ar;

[0302] 7.48, trd, 1H, Ar; 7.89, dd, 1H, Ar; 8.02, d, 1H, Ar; 8.20, s, 1H, CH=C; 10.60, s, ArOH Table 1: Compounds

[0303]

[0304] Example 2: Biodegradation

[0305] The compound samples were either used as such or prepared according to the quartz sand method as follows: For each test substance, a beaker and spatula were tared. Approximately 500 mg of the substance was weighed into the beaker and dissolved in about 5 mL of acetone. Just before adding the quartz sand, the beaker walls were rinsed with an additional 5 mL of acetone to ensure complete transfer of the sample.

[0306] Next, 10 g of preheated, washed quartz sand — free from organic matter — was added. The mixture was stirred continuously in an air stream for approximately 45 minutes until the consistency of the quartz sand and test substance mixture stabilized. A control test was also performed by mixing 10 g of quartz sand with 10 mL of acetone, followed by evaporation using the same procedure. All beakers were then left open in a fume cupboard to allow further evaporation of acetone. Three samples were taken from different areas of the quartz sand and analyzed for Total Organic Carbon (TOC) to determine the concentration of the test substance coated onto the sand surface. The test was initiated by adding buffer solution, sludge (final concentration: 30 mg / L), and the quartz sand coated with the test substance. The control setup included quartz sand treated only with acetone.

[0307] Biodegradation of the compounds was determined as follows:

[0308] OECD 301 F (BASF screening test): Biodegradation in wastewater was tested in triplicate using the OECD 301 F manometric respirometry method. OECD 301 F is an aerobic test that measures biodegradation of a sample by measuring the consumption of oxygen. To a measured volume of medium, 100 mg / L test substance (i.e. compound of formula (I)), which is the nominal sole source of carbon (either as such or prepared according to the quartz sand method) is added along with the inoculum (aerated sludge taken from Mannheim waste water treatment plant). This is stirred in a closed flask at a constant temperature of 22 °C for 28 days. The consumption of oxygen is determined by measuring the change in pressure in the apparatus using an OxiTopC. Evolved carbon dioxide is absorbed in a solution of sodium hydroxide. Nitrification inhibitors are added to the flask to prevent usage of oxygen due to nitrification. The amount of oxygen taken up by the microbial population during biodegradation of the test substance (corrected for uptake by blank inoculum, run in parallel) is expressed as a percentage of ThOD (theoretical oxygen demand, which is measured by the elemental analysis of the compound). A positive control Glucose / Glucosamine is run along with the test samples for each cabinet.

[0309] Biodegradation can then be calculated according to the following formula according to the OECD Guideline for the Testing of Chemicals, Section 3

[0310] BOD = (mg O2 uptake by test substance - mg O2 uptake by blank) I mg test substance in vessel

[0311] % degradation is calculated according to the following formula according to the OECD Guidelines for the Testing of Chemicals, Section 3:

[0312] % degradation = BOD / ThOD x 100

[0313] The results are shown in Table 2.

[0314] Table 2: Biodegradation

[0315] * indicates those compounds where the sample was prepared using the quartz sand method; in all other samples the compound was used as such (weigh in) Table 3

[0316] X max = wavelength in nm at extinction maximum in the range 290-420nm e11 = extinction at X max

[0317] Solvent = the solvent used in the measurement

Claims

Claims1. Compound of formula (I)or the salt, hydrate, tautomer or stereoisomer thereof; whereinR1is -Phenyl-(OR4)R2is H;R3is selected from C2-C12 alkyl;R4is -C(=O)R6;R6is C1-C4 alkyl.

2. The compound according to claim 1 , wherein(1) R3is linear or branched C3-C12 alkyl, preferably C3-, C4-, C5-, Ce-, C7-, Cs-, C9-, or Cio-alkyl, for example C4-Cio-alkyl, such as Cs-Cg-alkyl, in particular Ce-Cs-alkyl, preferably Cs-alkyl, more preferably branched Cs-alkyl, most preferably 2-ethylhexyl; and / or(2) R6is C1-C3 alkyl, preferably methyl or ethyl, more preferably methyl.

3. The compound according to claim 1 or 2, having the formula (la)or the salt, hydrate, tautomer or stereoisomer thereof.

4. The compound of any one of claims 1 to 3, wherein the compound has a biodegradability of at least 20% degradation, preferably at least 40%, more preferably at least 60 %, as determined over 28 days at 22°C according to OECD 301 F.

5. Composition comprising the organic biodegradable UV filter according to any one of claims 1 to 4, and optionally a dermatologically acceptable emulsifier, thickener, or emollient, preferably wherein the composition is a pharmaceutical or personal care composition.

6. The composition according to claim 5, further comprising at least one further UV filter different to the compounds of formula (I), preferably selected from(1) at least one UVA filter, preferably selected from the group consisting of disodium phenyl dibenzimidazole tetrasulfonate, hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate), methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate (MCE), 1-(4-(1 ,1- dimethylethyl)phenyl)-3-(4-methoxyphenyl)propane-1 ,3-dione (INCI butyl methoxydibenzoylmethane), terephthalylidene dicamphor sulfonic acid, and combinations thereof; and / or(2) at least one UVB filter, preferably selected from the group consisting of 4,4’,4”-(1 ,3,5-triazine-2,4,6- triyltriimino)tris-benzoic acid-tris(2-ethylhexyl)ester (INCI ethylhexyl triazone), 4,4’-[[6-[[4-[[(1 ,1- dimethylethyl)amino]carbonyl]phenyl]amino]-1 ,3,5-triazin-2,4-diyl]diimino]bis-benzoic acid-bis(2- ethylhexyl)ester (INCI diethylhexyl butamido triazone), phenylbenzimidazole sulfonic acid, , and combinations thereof; and / or(3) at least one broadband UV filter, preferably selected from the group consisting of bis- ethylhexyloxyphenol methoxyphenyl triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine), 2-(2H- benzotriazol-2-yl)-6-[(2-ethylhexyloxy)methyl]-4-methylphenol, 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2- methyl-3-[1 ,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]-1-disiloxanyl]propyl]phenol (INCI drometrizole trisiloxane), 2,2'-methylenbis[6-(2H-benzotriazol-2-yl)-4-(1 ,1 ,3,3-tetramethylbutyl)phenol] (INCI methylene Bis-benzotriazolyl tetramethylbutylphenol), phenylene bis-diphenyltriazine (PBDT), and combinations thereof; and / or(4) at least one organic particulate UV filter is selected from the group consisting of 2,2'-methylene bis[6- (2H-benzotriazol-2-yl)-4-(1 ,1 ,3,3-tetramethylbutyl)phenol] (INCI methylene bis-benzotriazolyl tetramethylbutylphenol), 2,4,6-tris(biphenyl-4-yl)-1 ,3,5-triazine (INCI tris-biphenyl triazine), 1 ,1 ’-(1 ,4- piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone (INCI bis- (diethylaminohydroxybenzoyl benzoyl) piperazine), 5,6,5’,6’-tetraphenyl-3-3’-(1 ,4-phenylene)bis(1 ,2,4- triazine) (INCI phenylene bis-diphenyltriazine, PBDT), micronized 1 ,4-di(benzoxazole-2'-yl)benzene and combinations thereof; and / or(5) at least one inorganic UV filter, preferably selected from the group consisting of titanium dioxide, zinc oxide, iron oxide, cerium oxide and mixtures thereof; and / or(6) at least one organic UV filter, preferably selected from the group consisting of ethylhexyl methoxycinnamate, ethylhexyl salicylate, homosalate, amiloxate, padimate O, shinorine, gadusol, mycosporine-2 glycine, porphyra-334, or cyanoacrylates, the cyanoacrylates optionally being selected from(7) at least one organic UV filter, preferably selected from the group consisting of croconic acid derivatives, N-[(3E)-3-[(4-Methoxyphenyl)imino]-5,5-dimethyl-1 -cyclohexen-1 -y l]g lyci n e , caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenyliminodimethylhexahydro benzothiazine carboxylic acid, Ethyl (3R)-3,4,5,6,7,8-hexahydro-8-[(4- methoxyphenyl)imino]-6,6-dimethyl-2H-1 ,4-benzothiazine-3-carboxylate, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, feruloyl hemp glycerides, feruloyl glycerides, feruloyl soybean glyceride FSG-33, feruloyl coconut glyceride FCG-33, feruloyl hemp glyceride FHG-33, ferulic acid, caffeic acid phenethyl ester, quercetin, methylsalicylate, vanillic acid, menthyl anthranilate, rutin, hispolon, Bis(cyano butylacetate) anthracenediylidene, trolamine salicylate, resveratrol trimethyl ether, ethyl ferulate, chlorogenic acid, methyl vanillate, ethyl protocatechuate, genistein, ellagic acid, pongamol, daidzein, luteolin, acetovanillone, caffeic acid, kaempferol, apigenin, sinapic acid, folic acid, troxerutin, p- coumaric acid, melanin, 3,4,5-trimethoxycinnamic acid, Kaempferia galanga root extract, ethylhexyl methoxycrylene, protocatechuic acid, lignin, lignosulfonate, coffee bean extract, mycosporine-like amino acids, gadusosporines, hipposudoric acid, norhipposudoric acid, 2-Methylphenyl (2E)-3-(4- methoxyphenyl)-2-propenoate, 2-Propenoic acid, 3-(4-methoxyphenyl)-, 2-methylphenyl ester.

7. The composition according to claim 5 or 6, further comprising one or more further biodegradable compounds selected from the group consisting of C12-C15 alkyl benzoates, coco glycerides, coconut oil, dibutyl adipate, dodecyl lactate, ethylhexyl benzoate, glycerol, glyceryl stearate, lauryl glycoside, lauryl lactate,(medium chain) triglycerides, phenoxyethanol, phenoxy ethyl caprylate, polyglyceryl-2- dipolyhydroxy-stearate, stearoyl glutamate and salts thereof, stearyl alcohol, dicarboxymethyl alaninate and salts thereof, xanthan gum, and ethanol.

8. The compound according to any one of claims 1 to 4 or the composition according to claim any one of claims 5 to 7 for use to protect skin against UV radiation.

9. Use of a compound of formula (I)or the salt, hydrate, tautomer or stereoisomer thereof; whereinR1is -Phenyl-(OR4)R2is H;R3is selected from C2-C12 alkyl;R4is -C(=O)R6;R6is C1-C4 alkyl, as an organic UV filter or as a light stabilizer to protect ingredients against photolytic degradation in a pharmaceutical, personal care or home care composition, wherein said UV filter of formula (I) optionally has a biodegradability of at least 20%, preferably at least 40%, according to OECD 301 F.

10. The composition of any one of claims 5 to 8 or the use according to claim 9, wherein the compound is comprised in said composition in an amount relative to the total weight of the composition of 0.5 to 50 wt.-%, preferably from 1 to 45 wt.-%, more preferably from 2 to 40 wt.-%, and in particular from 2.5 to 35 wt.-%.

Images